Adjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node

Wan Yu Chen; Ku Hao Fang; Chun Wei Wang; Chun Ta Liao; Tzue-Chen Yen; Taun Jen Fang; Shih Fan Lai; Hsiang Kuang Liang; Bing Shen Huang

doi:10.1002/lio2.679

Adjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node

Wan Yu Chen, Ku Hao Fang, Chun Wei Wang, Chun Ta Liao, Tzue-Chen Yen, Taun Jen Fang, Shih Fan Lai, Hsiang Kuang Liang, Bing Shen Huang^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

4 Scopus citations

Abstract

Objective: Whether to administer adjuvant treatment is a matter of great debate for oral cavity cancer harboring a single positive node without extranodal extension and positive margin (defined as low/intermediate risk pN1_new in this study). Methods: A total of 243 low/intermediate risk pN1_new patients with oral cavity cancer who received curative surgery were included. Overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) were compared between patients receiving adjuvant treatment and observation alone. Results: For patients receiving adjuvant therapy vs observation, the differences in outcomes were not statistically significant in terms of 5-year OS, LRFS, RRFS, and DMFS. For subgroup analysis, in low/intermediate pN1_new patients with one or more minor risk factors, adjuvant therapy was not significantly associated with OS, LRFS, RRFS, or DMFS in pN1_new patients. Conclusion: For low/intermediate risk pN1_new patients with oral cavity cancer, adjuvant therapy might be omitted. Level of Evidence: 4.

Original language	English
Pages (from-to)	1339-1346
Number of pages	8
Journal	Laryngoscope Investigative Otolaryngology
Volume	6
Issue number	6
DOIs	https://doi.org/10.1002/lio2.679
State	Published - 12 2021
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2021 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society.

Keywords

adjuvant radiotherapy
oral cancer
risk factor
single node
surgery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/lio2.679

Cite this

@article{a61727e52da24683b64ff40003cce7f0,

title = "Adjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node",

abstract = "Objective: Whether to administer adjuvant treatment is a matter of great debate for oral cavity cancer harboring a single positive node without extranodal extension and positive margin (defined as low/intermediate risk pN1new in this study). Methods: A total of 243 low/intermediate risk pN1new patients with oral cavity cancer who received curative surgery were included. Overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) were compared between patients receiving adjuvant treatment and observation alone. Results: For patients receiving adjuvant therapy vs observation, the differences in outcomes were not statistically significant in terms of 5-year OS, LRFS, RRFS, and DMFS. For subgroup analysis, in low/intermediate pN1new patients with one or more minor risk factors, adjuvant therapy was not significantly associated with OS, LRFS, RRFS, or DMFS in pN1new patients. Conclusion: For low/intermediate risk pN1new patients with oral cavity cancer, adjuvant therapy might be omitted. Level of Evidence: 4.",

keywords = "adjuvant radiotherapy, oral cancer, risk factor, single node, surgery",

author = "Chen, {Wan Yu} and Fang, {Ku Hao} and Wang, {Chun Wei} and Liao, {Chun Ta} and Tzue-Chen Yen and Fang, {Taun Jen} and Lai, {Shih Fan} and Liang, {Hsiang Kuang} and Huang, {Bing Shen}",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society.",

year = "2021",

month = dec,

doi = "10.1002/lio2.679",

language = "英语",

volume = "6",

pages = "1339--1346",

journal = "Laryngoscope Investigative Otolaryngology",

issn = "2378-8038",

publisher = "John Wiley and Sons Inc",

number = "6",

}

TY - JOUR

T1 - Adjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node

AU - Chen, Wan Yu

AU - Fang, Ku Hao

AU - Wang, Chun Wei

AU - Liao, Chun Ta

AU - Yen, Tzue-Chen

AU - Fang, Taun Jen

AU - Lai, Shih Fan

AU - Liang, Hsiang Kuang

AU - Huang, Bing Shen

PY - 2021/12

Y1 - 2021/12

N2 - Objective: Whether to administer adjuvant treatment is a matter of great debate for oral cavity cancer harboring a single positive node without extranodal extension and positive margin (defined as low/intermediate risk pN1new in this study). Methods: A total of 243 low/intermediate risk pN1new patients with oral cavity cancer who received curative surgery were included. Overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) were compared between patients receiving adjuvant treatment and observation alone. Results: For patients receiving adjuvant therapy vs observation, the differences in outcomes were not statistically significant in terms of 5-year OS, LRFS, RRFS, and DMFS. For subgroup analysis, in low/intermediate pN1new patients with one or more minor risk factors, adjuvant therapy was not significantly associated with OS, LRFS, RRFS, or DMFS in pN1new patients. Conclusion: For low/intermediate risk pN1new patients with oral cavity cancer, adjuvant therapy might be omitted. Level of Evidence: 4.

AB - Objective: Whether to administer adjuvant treatment is a matter of great debate for oral cavity cancer harboring a single positive node without extranodal extension and positive margin (defined as low/intermediate risk pN1new in this study). Methods: A total of 243 low/intermediate risk pN1new patients with oral cavity cancer who received curative surgery were included. Overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) were compared between patients receiving adjuvant treatment and observation alone. Results: For patients receiving adjuvant therapy vs observation, the differences in outcomes were not statistically significant in terms of 5-year OS, LRFS, RRFS, and DMFS. For subgroup analysis, in low/intermediate pN1new patients with one or more minor risk factors, adjuvant therapy was not significantly associated with OS, LRFS, RRFS, or DMFS in pN1new patients. Conclusion: For low/intermediate risk pN1new patients with oral cavity cancer, adjuvant therapy might be omitted. Level of Evidence: 4.

KW - adjuvant radiotherapy

KW - oral cancer

KW - risk factor

KW - single node

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=85117168793&partnerID=8YFLogxK

U2 - 10.1002/lio2.679

DO - 10.1002/lio2.679

M3 - 文章

AN - SCOPUS:85117168793

SN - 2378-8038

VL - 6

SP - 1339

EP - 1346

JO - Laryngoscope Investigative Otolaryngology

JF - Laryngoscope Investigative Otolaryngology

IS - 6

ER -

Adjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this